In the latest study, researchers targeted tumor-associated macrophages by mesothelin-targeting CAR (MCAR)-engineered MAIT (MCAR-MAIT) cells and found that the targeting and killing of tumor-associated macrophages by MCAR-MAIT cells may be the reason for their persistent tumor-killing ability and activation (109), supporting the human cancer therapeutic potential of CAR-MAIT cells. Here, MSLN is linked to neoplasm.